13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001475373
Total reported value
$461.0M
$461.0M
38 檔
20.3%
According to the latest 13F quarterly dataset, Sector Gamma As managed an equity portfolio of $461.0M at the end of Q2 2025, spanning 38 distinct U.S. exchange-listed positions.
Sector Gamma As executed strategic sector rebalancing during Q2 2025, establishing 6 new positions while fully exiting 1 holdings and trimming 17 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PFE | Pfizer Inc | Stock-Healthcare | 7.29% | -1.99% | -0.54% | |
| 2 | MDT | Medtronic plc | Stock-Healthcare | 6.38% | +0.24% | +9.27% | |
| 3 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 6.14% | -2.78% | -6.67% | |
| 4 | BDX | Becton Dickinson And Co | Stock-Healthcare | 5.52% | -0.01% | +19.51% | |
| 5 | MRK | Merck & Co. Inc. | Stock-Healthcare | 5.23% | -1.34% | — | |
| 6 | GILD | Gilead Sciences Inc | Stock-Healthcare | 4.60% | -1.75% | EXIT | |
| 7 | INCY | Incyte CORP | Stock-Healthcare | 4.54% | -0.26% | +28.30% | |
| 8 | AMGN | Amgen Inc | Stock-Healthcare | 4.02% | -1.86% | -25.42% | |
| 9 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 3.69% | +0.26% | — | |
| 10 | CVS | Cvs Health CORP | Stock-Healthcare | 3.68% | +1.19% | -19.31% | |
| 11 | CAH | Cardinal Health Inc | Stock-Healthcare | 3.62% | -0.64% | -25.00% | |
| 12 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 3.38% | +3.65% | NEW | |
| 13 | CNC | Centene CORP | Stock-Healthcare | 2.70% | +1.00% | -14.12% | |
| 14 | BAX | Baxter International Inc | Stock-Healthcare | 2.65% | — | +8.22% | |
| 15 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 2.64% | -0.67% | -22.00% | |
| 16 | BRKR | Bruker CORP | Stock-Healthcare | 2.64% | -0.18% | -7.55% | |
| 17 | ELV | Elevance Health Inc | Stock-Healthcare | 2.39% | +0.69% | -34.75% | |
| 18 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 2.20% | +0.46% | -10.92% | |
| 19 | BIIB | Biogen Inc | Stock-Healthcare | 2.08% | -1.36% | +171.68% | |
| 20 | HUM | Humana Inc | Stock-Healthcare | 1.88% | -0.79% | EXIT | |
| 21 | QGEN | Qiagen N.V. | Stock-Healthcare | 1.84% | — | -37.43% | |
| 22 | GEHC | GE Healthcare Technology | Stock-Healthcare | 1.79% | +0.77% | +19.35% | |
| 23 | LH | Labcorp Holdings Inc | Stock-Healthcare | 1.67% | +0.38% | — | |
| 24 | AVTR | Avantor Inc | Stock-Healthcare | 1.64% | +0.66% | — | |
| 25 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 1.47% | +0.56% | — | |
| 26 | DXCM | Dexcom Inc | Stock-Healthcare | 1.43% | +0.66% | — | |
| 27 | BIO | Bio-rad Laboratories-a | Stock-Healthcare | 1.41% | +0.56% | +28.92% | |
| 28 | ELAN | Elanco Animal Health Inc | Stock-Healthcare | 1.36% | — | -38.78% | |
| 29 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 1.35% | -1.67% | EXIT | |
| 30 | BNTX | Biontech Se-adr | Stock-Other | 1.30% | — | +24.90% | |
| 31 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 1.28% | -0.34% | +16.62% | |
| 32 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.07% | +0.05% | -65.85% | |
| 33 | HCA | Hca Healthcare Inc | Stock-Healthcare | 1.00% | — | — | |
| 34 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 0.96% | — | +49.09% | |
| 35 | ASND | Ascendis Pharma A/S | Stock-Other | 0.96% | -1.15% | EXIT | |
| 36 | SOLV | Solventum CORP | Stock-Healthcare | 0.94% | — | +26.67% | |
| 37 | THC | Tenet Healthcare CORP | Stock-Healthcare | 0.72% | — | -70.93% | |
| 38 | ACLXGBX | Arcellx Inc | Stock-Other | 0.54% | — | -28.57% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MRK | Merck & Co. Inc. | +5.2% | NEW | New buy |
| 2 | TMO | Thermo Fisher Scientific Inc | +3.4% | NEW | New buy |
| 3 | LH | Labcorp Holdings Inc | +1.7% | NEW | New buy |
| 4 | AVTR | Avantor Inc | +1.6% | NEW | New buy |
| 5 | INCY | Incyte CORP | +1.5% | +28.30% | Add |
| 6 | DXCM | Dexcom Inc | +1.4% | NEW | New buy |
| 7 | BIIB | Biogen Inc | +1.3% | +171.68% | Add |
| 8 | HCA | Hca Healthcare Inc | +1% | NEW | New buy |
| 9 | IONS | Ionis Pharmaceuticals Inc | +0.9% | — | Unchanged |
| 10 | LNTH | Lantheus Holdings Inc | +0.6% | +101.20% | Add |
| 11 | MDT | Medtronic plc | +0.5% | +9.27% | Add |
| 12 | BNTX | Biontech Se-adr | +0.4% | +24.90% | Add |
| 13 | BIO | Bio-rad Laboratories-a | +0.3% | +28.92% | Add |
| 14 | TGTX | Tg Therapeutics Inc | +0.3% | +49.09% | Add |
| 15 | SOLV | Solventum CORP | +0.2% | +26.67% | Add |
| 16 | GEHC | GE Healthcare Technology | +0.2% | +19.35% | Add |
| 17 | TNDM | Tandem Diabetes Care Inc | +0.2% | +16.62% | Add |
| 18 | ASND | Ascendis Pharma A/S | +0.1% | — | Unchanged |
| 19 | PTCT | Ptc Therapeutics Inc | 0% | — | Unchanged |
| 20 | BAX | Baxter International Inc | -0.1% | +8.22% | Add |
| 21 | BRKR | Bruker CORP | -0.2% | -7.55% | Trim |
| 22 | ACLXGBX | Arcellx Inc | -0.2% | -28.57% | Trim |
| 23 | PFE | Pfizer Inc | -0.2% | -0.54% | Trim |
| 24 | HUM | Humana Inc | -0.2% | -6.00% | Trim |
| 25 | ELAN | Elanco Animal Health Inc | -0.2% | -38.78% | Trim |
| 26 | CAH | Cardinal Health Inc | -0.3% | -25.00% | Trim |
| 27 | GILD | Gilead Sciences Inc | -0.4% | -9.29% | Trim |
| 28 | BDX | Becton Dickinson And Co | -0.5% | +19.51% | Add |
| 29 | QGEN | Qiagen N.V. | -0.6% | -37.43% | Trim |
| 30 | CVS | Cvs Health CORP | -0.7% | -19.31% | Trim |
| 31 | CNC | Centene CORP | -0.7% | -14.12% | Trim |
| 32 | BMRN | Biomarin Pharmaceutical Inc | -0.9% | -10.92% | Trim |
| 33 | THC | Tenet Healthcare CORP | -1.1% | -70.93% | Trim |
| 34 | ZBH | Zimmer Biomet Holdings Inc | -1.5% | -22.00% | Trim |
| 35 | ELV | Elevance Health Inc | -1.6% | -34.75% | Trim |
| 36 | EW | Edwards Lifesciences CORP | -1.8% | -65.85% | Trim |
| 37 | AMGN | Amgen Inc | -1.9% | -25.42% | Trim |
| 38 | BMY | Bristol-myers Squibb Co | -2.4% | -6.67% | Trim |
| 39 | JNJ | Johnson & Johnson | -5.2% | EXIT | Sold out |
According to official SEC Form 13F filings, Sector Gamma As reported a total U.S. public equity portfolio value of $461.0M across 38 disclosed positions in Q2 2025.
During Q2 2025, Sector Gamma As's top holdings by market value included PFE (7.3%)、MDT (6.4%)、BMY (6.1%). The largest single position, PFE, represented 7.3% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PFE, MDT, BMY) accounted for 20.3% of total reported equity market value during Q2 2025.
Top New Position Initiated
MRK
市值: $16.0M
Top Position Liquidated / Trimmed
JNJ
前期市值: $16.3M
In Q2 2025, Sector Gamma As made 36 total portfolio adjustments, initiating 6 new buys, adding to 12 positions, trimming 17 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.